scholarly journals Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs

Oncotarget ◽  
2015 ◽  
Vol 6 (36) ◽  
pp. 38504-38516 ◽  
Author(s):  
Ming Zhou ◽  
Lei Wang ◽  
Songqin Zhou ◽  
Zhao Wang ◽  
Juncheng Ruan ◽  
...  
2019 ◽  
Vol 55 (2) ◽  
pp. 399 ◽  
Author(s):  
Kerri Pedersen ◽  
Amy T. Gilbert ◽  
Eric S. Wilhelm ◽  
Kathleen M. Nelson ◽  
Amy J. Davis ◽  
...  

2021 ◽  
Vol 63 (1) ◽  
Author(s):  
Ad Vos ◽  
Tiina Nokireki ◽  
Marja Isomursu ◽  
Tuija Gadd ◽  
Ferenc Kovacs

Abstract Background To prevent re-emergence of wildlife-mediated rabies in Finland, oral rabies vaccine baits are distributed every year during autumn in southern Finland in a vaccination zone bordering Russia. Recently, Finland introduced a 3rd generation oral rabies virus vaccine bait. By analysing bait uptake and seroconversion in red foxes and raccoon dogs, the field efficacy of this new vaccine strain, SPBN GASGAS, was compared with the originally used highly efficacious 1st generation vaccine SAD B19. Results Overall, 74.6% and 53.9% of the animals submitted from the vaccination area after the campaigns (2017–2019) tested positive for the presence of the bait marker and anti-rabiesvirus antibodies, respectively. No significant difference was observed between years, species and vaccine. Conclusions The field performance of the highly attenuated 3rd generation oral rabies vaccine, SPBN GASGAS, in terms of bait uptake and seroconversion was similar to the 1st generation vaccine, SAD B19, and therefore offers a suitable alternative.


Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 573
Author(s):  
Kansuda Leelahapongsathon ◽  
Suwicha Kasemsuwan ◽  
Tanu Pinyopummintr ◽  
Orawan Boodde ◽  
Parinya Phawaphutayanchai ◽  
...  

Applied research is crucial in pushing the boundaries and finding a solution to the age-old problem of dog-mediated rabies. Although oral vaccination of dogs is considered to have great potential in mass dog vaccination campaigns and could have far-reaching benefits, it is perhaps the most ignored of all available tools in efforts to eliminate dog-mediated rabies, not least because of limited data on immunogenicity, efficacy, and safety of potential oral rabies vaccine candidates. In this study, the long-term immunogenicity in local Thai dogs after oral administration of the highly attenuated 3rd generation rabies virus vaccine strain SPBN GASGAS was assessed. The oral rabies vaccine was administered to dogs by either direct oral administration (n = 10) or by offering a vaccine loaded intestine bait (n = 15). The humoral immune response was then compared to three groups of dogs; a group that received a parenteral delivered inactivated rabies vaccine (n = 10), a group offered a placebo intestine bait (n = 7), and a control group (n = 4) for an observation period of 365 days. There was no significant difference in the immune response of dogs that received oral and parenteral vaccine in terms of magnitude, kinetics, and persistence of both rabies virus (RABV) neutralizing (RFFIT) and binding (ELISA) antibodies. Although the single parenteral injection of an inactivated rabies vaccine mounted a slightly higher humoral immune response than the orally delivered live vaccine, RABV specific antibodies of both types were still detectable after one year in most animals for all treatment groups and resulted in no difference in seropositivity. Characterization of rabies specific antibodies revealed two main classes of antibodies involved in the immune response of dogs vaccinated. While IgM antibodies were the first to appear, the succeeding IgG response was mainly IgG2 dominated independent of the vaccine type used. The results support the view that SPBN GASGAS induces a sustained detectable immune response in local dogs both after direct oral administration and via bait application.


Vaccines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 49
Author(s):  
Verena te Kamp ◽  
Virginia Friedrichs ◽  
Conrad M. Freuling ◽  
Ad Vos ◽  
Madlin Potratz ◽  
...  

The live genetically-engineered oral rabies virus (RABV) variant SPBN GASGAS induces long-lasting immunity in foxes and protection against challenge with an otherwise lethal dose of RABV field strains both after experimental oral and parenteral routes of administration. Induction of RABV-specific binding antibodies and immunoglobulin isotypes (IgM, total IgG, IgG1, IgG2) were comparable in orally and parenterally vaccinated foxes. Differences were only observed in the induction of virus-neutralizing (VNA) titers, which were significantly higher in the parenterally vaccinated group. The dynamics of rabies-specific antibodies pre- and post-challenge (365 days post vaccination) suggest the predominance of type-1 immunity protection of SPBN GASGAS. Independent of the route of administration, in the absence of IgG1 the immune response to SPBN GAGAS was mainly IgG2 driven. Interestingly, vaccination with SPBN GASGAS does not cause significant differences in inducible IFN-γ production in vaccinated animals, indicating a relatively weak cellular immune response during challenge. Notably, the parenteral application of SPBN GASGAS did not induce any adverse side effects in foxes, thus supporting safety studies of this oral rabies vaccine in various species.


1989 ◽  
Vol 25 (1) ◽  
pp. 1-9 ◽  
Author(s):  
J. Hadidian ◽  
S. R. Jenkins ◽  
D. H. Johnston ◽  
P. J. Savarie ◽  
V. F. Nettles ◽  
...  

1988 ◽  
Vol 24 (3) ◽  
pp. 477-483 ◽  
Author(s):  
Erich H. Follmann ◽  
Donald G. Ritter ◽  
George M. Baer

2000 ◽  
Vol 36 (4) ◽  
pp. 744-751 ◽  
Author(s):  
H. Grant Steelman ◽  
Scott E. Henke ◽  
Guy M. Moore

2007 ◽  
Vol 45 (5) ◽  
pp. 451-453
Author(s):  
Rita Mrvos ◽  
Edward P. Krenzelok

2019 ◽  
Vol 26 (10) ◽  
pp. 9816-9822 ◽  
Author(s):  
Betsy S. Haley ◽  
Are R. Berentsen ◽  
Richard M. Engeman

2017 ◽  
Vol 53 (2) ◽  
pp. 424-427 ◽  
Author(s):  
Tad Theimer ◽  
Tisheena Talk ◽  
Shylo Johnson ◽  
David L. Bergman

Sign in / Sign up

Export Citation Format

Share Document